5XCV | pdb_00005xcv

Crystal structure of NZ-1 Fv-clasp fragment with its antigen peptide


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.14 Å
  • R-Value Free: 
    0.277 (Depositor), 0.275 (DCC) 
  • R-Value Work: 
    0.228 (Depositor), 0.229 (DCC) 
  • R-Value Observed: 
    0.231 (Depositor) 

Starting Models: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 5XCV

This is version 1.3 of the entry. See complete history

Literature

Fv-clasp: An Artificially Designed Small Antibody Fragment with Improved Production Compatibility, Stability, and Crystallizability

Arimori, T.Kitago, Y.Umitsu, M.Fujii, Y.Asaki, R.Tamura-Kawakami, K.Takagi, J.

(2017) Structure 25: 1611-1622.e4

  • DOI: https://doi.org/10.1016/j.str.2017.08.011
  • Primary Citation Related Structures: 
    5XCQ, 5XCR, 5XCS, 5XCT, 5XCU, 5XCV, 5XCX

  • PubMed Abstract: 

    Antibody fragments are frequently used as a "crystallization chaperone" to aid structural analysis of complex macromolecules that are otherwise crystallization resistant, but conventional fragment formats have not been designed for this particular application. By fusing an anti-parallel coiled-coil structure derived from the SARAH domain of human Mst1 kinase to the variable region of an antibody, we succeeded in creating a novel chimeric antibody fragment of ∼37 kDa, termed "Fv-clasp," which exhibits excellent crystallization compatibility while maintaining the binding ability of the original IgG molecule. The "clasp" and the engineered disulfide bond at the bottom of the Fv suppressed the internal mobility of the fragment and shielded hydrophobic residues, likely contributing to the high heat stability and the crystallizability of the Fv-clasp. Finally, Fv-clasp antibodies showed superior "chaperoning" activity over conventional Fab fragments, and facilitated the structure determination of an ectodomain fragment of integrin α6β1.


  • Organizational Affiliation
    • Institute for Protein Research, Osaka University, Suita, Osaka 565-0871, Japan.

Macromolecule Content 

  • Total Structure Weight: 78.69 kDa 
  • Atom Count: 5,486 
  • Modeled Residue Count: 665 
  • Deposited Residue Count: 702 
  • Unique protein chains: 3

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
VH(S112C)-SARAH chimera,VH(S112C)-SARAH chimera
A, D
172RattusHomo sapiens
This entity is chimeric
Mutation(s): 0 
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
VL-SARAH(S37C) chimera,VL-SARAH(S37C) chimera
B, E
165RattusHomo sapiens
This entity is chimeric
Mutation(s): 0 
Find similar proteins by:  Sequence   |   3D Structure  
Entity ID: 3
MoleculeChains  Sequence LengthOrganismDetailsImage
PA14 peptide
C, F
14Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for Q86YL7 (Homo sapiens)
Explore Q86YL7 
Go to UniProtKB:  Q86YL7
PHAROS:  Q86YL7
GTEx:  ENSG00000162493 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ86YL7
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.14 Å
  • R-Value Free:  0.277 (Depositor), 0.275 (DCC) 
  • R-Value Work:  0.228 (Depositor), 0.229 (DCC) 
  • R-Value Observed: 0.231 (Depositor) 
Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 145.617α = 90
b = 50.122β = 110.46
c = 121.868γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2017-10-11
    Type: Initial release
  • Version 1.1: 2017-10-18
    Changes: Database references
  • Version 1.2: 2023-11-22
    Changes: Data collection, Database references, Derived calculations, Refinement description
  • Version 1.3: 2024-10-23
    Changes: Structure summary